Humacyte Prices $50 Million Public Offering to Support Commercial Launch and Pipeline Development

Humacyte Inc. (NASDAQ: HUMA) announced the pricing of an underwritten public offering of 47.6 million shares of common stock at $1.05 per share, with expected gross proceeds of approximately $50 million before underwriting discounts, commissions and offering expenses. The company also granted underwriters a 30-day option to purchase up to an additional 7.1 million shares at the public offering price. The offering is expected to close on or about June 12, 2026, subject to customary closing conditions.

Humacyte said it intends to use the net proceeds to support commercialization of Symvess, advance a planned Biologics License Application supplement filing for a hemodialysis indication, fund development of pipeline candidates and provide working capital for general corporate purposes. Barclays, BTIG and Titan Partners, a division of American Capital Partners, are serving as joint book-running managers for the offering. For further details, the full press release is available at https://ibn.fm/k6T1b.

Humacyte is a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale. In the first quarter of 2025, the company commenced the United States commercial launch of Symvess, its first FDA-approved product. Humacyte is pioneering the development and manufacture of off-the-shelf, universally implantable, bioengineered human tissues, advanced tissue constructs and organ systems with the goal of improving the lives of patients and transforming the practice of medicine. The company leverages its novel, scalable technology platform to develop proprietary, bioengineered, acellular human tissues for use in the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas.

The funding comes at a critical time as Humacyte seeks to establish a foothold in the vascular trauma market with Symvess and expand its indications. The planned Biologics License Application supplement for hemodialysis access represents a significant potential market opportunity, as millions of patients worldwide require reliable vascular access for dialysis. Success in this indication could drive substantial revenue growth and validate the platform’s broader applicability.

Investors will be watching how the company deploys the capital to achieve commercial milestones and advance its pipeline. The offering also provides working capital to support general corporate purposes, which may include manufacturing scale-up, sales force expansion, and research and development activities. With the additional share option for underwriters, the total potential capital raise could reach approximately $57.5 million if the option is fully exercised.

For uses other than the U.S. Food and Drug Administration approval in the extremity vascular trauma indication, the acellular tissue engineered vessel is an investigational product and has not been approved for sale by the FDA or any other regulatory agency. More information about Humacyte is available on its website at https://humacyte.com/.

This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Humacyte Prices $50 Million Public Offering to Support Commercial Launch and Pipeline Development.

The post Humacyte Prices $50 Million Public Offering to Support Commercial Launch and Pipeline Development appeared first on citybuzz.